Aclarion, Inc. (ACON) is experiencing a notable surge in its stock price, with a premarket increase of 10.7%, bringing the price to $5.17. This uptick comes on the heels of the company's recent announcement regarding a new patent that significantly expands its technological capabilities.
The United States Patent and Trademark Office (USPTO) has granted Aclarion a Notice of Allowance for its 24th issued patent, which enhances the company's ability to utilize Magnetic Resonance Spectroscopy (MRS) in identifying propionic acid (PA) as a biomarker for pain and infection throughout the body. Previously, Aclarion's patents were limited to the use of MRS for identifying PA only in intervertebral discs. This new patent broadens their scope, allowing for potential applications in various medical scenarios.
Jeff Lotz, PhD, Vice Chair of Research at the University of California at San Francisco, highlighted the implications of this patent, stating, "Aclarion is a global leader in harnessing the power of MR spectroscopy, and this recent patent addition further expands the potential for Aclarion to commercialize the use of MRS beyond discogenic low back pain to encompass identifying and measuring propionic acid throughout the body." This statement underscores the significant impact this patent could have on Aclarion's future operations and market position.
The MRS technology is crucial as it provides insights into various chemical biomarkers, enhancing the accuracy of diagnoses related to chronic low back pain and other conditions. With this patent, Aclarion is poised to strengthen its market presence and offer innovative solutions to healthcare providers.
With a trading volume of 1,249,456 shares in premarket, investors are keenly watching Aclarion's progress as it continues to develop its proprietary technologies. The positive reception of this patent news may lead to further stock price movements as the market reacts to Aclarion's expanding capabilities.
